The efficacy and role of afatinib: How to accurately target lung cancer cells?

Afatinib is a targeted anticancer drug mainly used to treat patients with non-small cell lung cancer (NSCLC), especially those with epidermal growth factor receptor (EGFR) mutations. As an oral drug, afatinib precisely inhibits the growth and spread of tumor cells by blocking the EGFR signaling pathway, thereby effectively treating lung cancer and improving the quality of life of patients.

EGFR mutation is one of the most common driver mutations in non-small cell lung cancer, especially in Asian populations, where approximately 40% to 50% of patients have such mutations. These mutations lead to overactivation of the EGFR receptor, thereby promoting cancer cell proliferation and tumor progression. As an irreversible EGFR inhibitor, afatinib binds to the EGFR receptor and prevents its activation, thus blocking the transmission of downstream signaling pathways and inhibiting the growth, spread and metastasis of tumor cells.

The mechanism of action of afatinib is its unique design at the molecular level. Unlike traditional reversible inhibitors, afatinib can irreversibly bind to the EGFR receptor to provide a more durable inhibitory effect. It not only has an inhibitory effect on common mutation types of EGFR (such as L858R and Exon 19 deletion), but also effectively inhibits the EGFR T790M mutation (this mutation is usually resistant to first-generation EGFR inhibitors) and the activation of related receptors such as HER2 and ErbB2. Therefore, afatinib can cover a wider range of mutation types and can also produce therapeutic effects in some patients with drug-resistant EGFR mutations.

In clinical application, the efficacy of afatinib has been widely verified. According to a number of international clinical studies, afatinib, as a second-line or third-line treatment drug, has shown relatively obvious efficacy in patients with EGFR mutant non-small cell lung cancer. Especially in a global multi-center clinical trial called LUX-Lung 3, afatinib significantly improved the progression-free survival (PFS) of patients, and its efficacy has been widely recognized compared with traditional chemotherapy drugs. In addition, afatinib has been proven to significantly improve the objective response rate (ORR) in certain patient groups and help patients achieve tumor shrinkage or stabilization.

The side effects of afatinib are relatively common, especially adverse reactions such as rash, diarrhea, and oral ulcers, which are related to the skin and gastrointestinal reactions caused by its inhibitory effect onEGFR. Most adverse reactions can be alleviated by appropriate supportive care, and as treatment continues, the side effects of some patients will gradually decrease. In addition, in a small number of patients, serious adverse reactions such as liver function damage may occur, so liver function and other biochemical indicators need to be monitored regularly during treatment.

To ensure the maximum efficacy and safety of the drug, patients should strictly follow their doctor's recommendations when using afatinib, especially with regard to dose adjustment. Normally, the recommended starting dose of afatinib is 40 mg per day, but in some patients, if the adverse reactions are severe, doctors may reduce the dose appropriately based on the patient's tolerance. Patients also need to undergo regular imaging examinations and biomarker testing during treatment to ensure the efficacy of the drug and detect possible drug resistance in a timely manner.

Reference materials:https://www.giotrif.com/